30241-37-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Cyclopentyl-5-methyl-2H-pyrazol-3-ylamine is used as a building block for the synthesis of pharmaceutical drugs. Its unique structure allows for the development of new medications with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Cyclopentyl-5-methyl-2H-pyrazol-3-ylamine serves as a key component in the creation of agrochemicals, contributing to the development of effective pest control and crop protection solutions.
Used as a Reagent in Organic Chemistry:
2-Cyclopentyl-5-methyl-2H-pyrazol-3-ylamine is utilized as a reagent in organic chemistry reactions, particularly in the formation of new carbon-carbon bonds. Its presence facilitates the synthesis of complex organic molecules for various applications.
Used in Biological and Pharmacological Research:
CP-30615 has been studied for its potential biological and pharmacological properties, including its role as an inhibitor of certain enzymes. This research aims to uncover its therapeutic potential and contribute to the advancement of medical treatments.

InChI:InChI=1/C9H15N3/c1-7-6-9(10)12(11-7)8-4-2-3-5-8/h6,8H,2-5,10H2,1H3

Upstream product

• 646071-31-0 tert-butyl 2-cyclopentylhydrazinecarboxylate 
• 120-92-3 cyclopentanone 
• 2469-99-0 Cyanoaceton 
• 30923-92-3 cyclopentylhydrazine 
• 1118-61-2 3-Aminocrotononitrile 
• 24214-72-0 cyclopentylhydrazine hydrochloride 

Downstream Products

• 1616512-12-9 1-cyclopentyl-4-(4-fluorobenzoyl)-3-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one 
• 1616512-11-8 1-cyclopentyl-4-(4-methoxybenzoyl)-3-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one 
• 1616512-10-7 1-cyclopentyl-3-methyl-4-(4-methylbenzoyl)-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one 
• 1616512-09-4 4-benzoyl-1-cyclopentyl-3-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one 
• 1027503-41-8 4-chloro-1-cyclopentyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl chloride 

Relevant academic research and scientific papers

Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators

The G protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) are a family of inward-rectifying potassium channels, and there is significant evidence supporting the roles of GIRKs in a number of physiological processes and as potential targets for numerous indications. Previously reported urea containing molecules as GIRK1/2 preferring activators have had significant pharmacokinetic (PK) liabilities. Here we report a novel series of 1H-pyrazolo-5-yl-2-phenylacetamides in an effort to improve upon the PK properties. This series of compounds display nanomolar potency as GIRK1/2 activators with improved brain distribution (rodent Kp > 0.6).

AZAINDAZOLES

Herein are disclosed azaindazoles of formula (I), (I), where the various groups are defined herein, and which are useful for treating cancer.

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.